Mondego Bio
PrivateLast Round
Series A
Sep 18, 2025
Total Funding Raised
$23.74M
Company Overview
Mondego Bio is a biotechnology company developing best-in-class Protein tyrosine phosphatase non-receptor type 2 (PTPN2) inhibitors for immuno-oncological therapy.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials
Business Model
B2B
Customer Profile
Revenue Share
AI Layer
Non-AI
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Mondego Bio Comps
Public and private peers based on sector, stage, and business model.
Mondego Bio Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Sep 18, 2025 |
Mondego Bio Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| OrbiMed | Series A |
| Biovance Capital Partners | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Oct 8, 2025
Added Biovancecapital, a startup VC, as a customer.
- Oct 8, 2025
Added OrbiMed, a healthcare investment firm, as a customer.
Mondego Bio Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Mondego Bio's valuation, stock price, and market status.
